NCT05157997View on ClinicalTrials.gov

Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2022

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2025

Conditions
COVID-19Organ Transplant
Interventions
DRUG

Casirivimab and Imdevimab Antibody Cocktail

The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.

Trial Locations (1)

11030

Northwell Health Organ Transplant Center, Manhasset

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Northwell Health

OTHER

NCT05157997 - Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail | Biotech Hunter | Biotech Hunter